The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The NDA 21-130 Zyvox (linezolid tablets) Drug Master File in Japan (NDA 21-130 Zyvox (linezolid tablets) JDMF) empowers NDA 21-130 Zyvox (linezolid tablets) API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the NDA 21-130 Zyvox (linezolid tablets) JDMF during the approval evaluation for pharmaceutical products. At the time of NDA 21-130 Zyvox (linezolid tablets) JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of NDA 21-130 Zyvox (linezolid tablets) suppliers with JDMF on PharmaCompass.